|
|
Article: B-MS and Otsuka's Abilify oral solution approved by FDA.(Bristol-Myers Squibb Co.; Otsuka Pharmaceutical Company Ltd.)(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- January 3, 2005
CopyrightCOPYRIGHT 2005 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
US health care giant Bristol-Myers Squibb and Japanese drugmaker Otsuka Pharmaceutical say they have received US Food and Drug Administration approval for an oral formulation of Abilify (aripiprazole), which is indicated for the treatment of schizophrenia and acute manic and mixed episodes associated with bipolar disorder ...
Related newspaper, magazine, and journal articles:
|
|
Article: Bristol-Myers Squibb and Otsuka ...
PR Newswire;
March 5, 2008 ;
700+ words
... ... a new report that finds that Bristol-Myers Squibb and Otsuka Pharmaceutical spend almost twice as much on Abilify ... and fewer than 10% mention Bristol- Myers Squibb or Otsuka Pharmaceutical as a top-of-mind company in atypical ...
|
|